Invention Grant
US07642263B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
失效
用作治疗糖尿病的GLK激活剂的杂芳基苯甲酰胺衍生物
- Patent Title: Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
- Patent Title (中): 用作治疗糖尿病的GLK激活剂的杂芳基苯甲酰胺衍生物
-
Application No.: US12202800Application Date: 2008-09-02
-
Publication No.: US07642263B2Publication Date: 2010-01-05
- Inventor: Darren McKerrecher , Kurt Gordon Pike , Michael James Waring
- Applicant: Darren McKerrecher , Kurt Gordon Pike , Michael James Waring
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: Morgan, Lewis & Bockius LLP
- Priority: GB0514173.4 20050709; GB0516297.9 20050809; GB0523862.1 20051124; GB0524589.9 20051202; GB0607977.6 20060422
- Main IPC: A61K31/4965
- IPC: A61K31/4965
Abstract:
Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and prodrugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
Public/Granted literature
- US20090029905A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES Public/Granted day:2009-01-29
Information query
